DNA LEVEL STUDY OF ALLOREACTIVE T-CELL CLONE TARGETS

同种反应性 T 细胞克隆靶标的 DNA 水平研究

基本信息

项目摘要

Using restriction fragment length polymorphism analysis (RFLP), three allelic DQ-alpha and three allelic DQ-beta patterns associated DQw1 have been recognized. One of these alpha/beta pairs was found to associate with DR1, two with DR2, and a fourth with DRw6. "Complementary" alloreactive T-cell clones were generated that were able to specifically recognize one or the other of the two DR2 associated, DQw1-positive molecules of the stimulator cells. These molecules carry the same alpha chain but a different (allelic) form of beta chain. In the last few months, evidence has also been obtained by nucleotide sequencing that there are as many allelic forms of DQ-alpha and DQ-beta genes as there are different molecular DQ-alpha and DQ-beta (RFLP) patterns, and each alpha/beta gene combination is associated with the same DR allele as its corresponding molecular alpha/beta pattern pair. It would now be certainly interesting to definitively prove that: a) antibodies may recognize determinants present only on the alpha or on the beta chain of the DQ molecule, while T-cells recognize simultaneously alpha and beta determinants. An allelic modification on only one chain is sufficient to completely abrogate the T-cell alloreaction, but may not interfere with the ability of the antibodies to recognize other epitopes or epitopes of the other chain; b) specificities, against which reagents in general cannot be found because of the strong association of certain alpha with certain beta genes, can be artificially generated by co-transfecting alpha and beta genes in anusual associations; c) specific reagents (monoclonal antibodies as well as T-cell clones) can be generated against these "new" specificities. The spontaneous generation of these "new" specificities may rarely take place by transcomplementation in the presence of particular haplotype combinations. This may be the cause of the immunological failure or the immunological auto-aggression which has generally been found present in the majority of HLA associated diseases. The reagents generated against the artificially obtained "new" specificities would be useful for the early recognition of their presence at the surface of the patient cells.
使用限制性片段长度多态性分析(RFLP), 三个等位基因DQ-α和三个等位基因DQ-β模式 已识别出相关的DQw 1。 其中一个alpha/beta 发现有2对与DR 1相关,2对与DR 2相关, 第四个是DRW 6。 “互补”同种异体反应性T细胞克隆 能够特异性地识别一个或多个 两个DR 2相关的DQw 1阳性分子中的另一个 刺激细胞 这些分子携带着相同的α链 而是β链的不同(等位)形式。 过去几 几个月后,通过核苷酸测序, DQ-α和DQ-β的等位基因 因为有不同的分子DQ-α和DQ-β (RFLP)模式,每个α/β基因组合是 与其相应分子的相同DR等位基因相关 Alpha/Beta模式对。 现在, 明确证明:a)抗体可以识别决定簇 仅存在于DQ的α链或β链上 分子,而T细胞同时识别α和β 决定因素 仅在一条链上的等位基因修饰是 足以完全消除T细胞同种异体反应,但可能 不干扰抗体识别其他抗体的能力, 表位或其它链的表位; B)特异性,针对 这些试剂通常不能被发现,因为 某些α基因与某些β基因的关联, 人工合成的α和β基因 异常关联; c)特异性试剂(单克隆抗体 以及T细胞克隆)可以针对这些“新的” 特殊性 这些“新”特异性的自发产生可能 很少发生反式互补, 特定的单倍型组合。 这可能是导致 免疫失败或免疫性自我攻击, 在大多数HLA中普遍存在 相关疾病。 生成的试剂针对 人工获得的“新”特异性将有助于 早期识别它们在患者体表的存在 细胞

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MASSIMO M. TRUCCO其他文献

MASSIMO M. TRUCCO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MASSIMO M. TRUCCO', 18)}}的其他基金

Humoral And Cellular Tolerization Approaches Against Au*
针对 Au* 的体液和细胞耐受方法
  • 批准号:
    6872007
  • 财政年份:
    2003
  • 资助金额:
    $ 15.87万
  • 项目类别:
Humoral And Cellular Tolerization Approaches Against Au*
针对 Au* 的体液和细胞耐受方法
  • 批准号:
    6803537
  • 财政年份:
    2003
  • 资助金额:
    $ 15.87万
  • 项目类别:
Humoral And Cellular Tolerization Approaches Against Au*
针对 Au* 的体液和细胞耐受方法
  • 批准号:
    6684628
  • 财政年份:
    2003
  • 资助金额:
    $ 15.87万
  • 项目类别:
Humoral And Cellular Tolerization Approaches Against Autoimmunity
对抗自身免疫的体液和细胞耐受方法
  • 批准号:
    7228440
  • 财政年份:
    2003
  • 资助金额:
    $ 15.87万
  • 项目类别:
Humoral And Cellular Tolerization Approaches Against Au*
针对 Au* 的体液和细胞耐受方法
  • 批准号:
    7038210
  • 财政年份:
    2003
  • 资助金额:
    $ 15.87万
  • 项目类别:
Optical Imaging of Beta-Cell Function and Engraftment
β 细胞功能和植入的光学成像
  • 批准号:
    6666714
  • 财政年份:
    2002
  • 资助金额:
    $ 15.87万
  • 项目类别:
Gene-engineered dendritic cell therapy for diabetics
针对糖尿病患者的基因工程树突状细胞疗法
  • 批准号:
    6666777
  • 财政年份:
    2002
  • 资助金额:
    $ 15.87万
  • 项目类别:
Gene-engineered dendritic cell therapy for diabetics
针对糖尿病患者的基因工程树突状细胞疗法
  • 批准号:
    7119507
  • 财政年份:
    2002
  • 资助金额:
    $ 15.87万
  • 项目类别:
Optical Imaging of Beta-Cell Function and Engraftment
β 细胞功能和植入的光学成像
  • 批准号:
    6574526
  • 财政年份:
    2002
  • 资助金额:
    $ 15.87万
  • 项目类别:
Gene-engineered dendritic cell therapy for diabetics
针对糖尿病患者的基因工程树突状细胞疗法
  • 批准号:
    7085769
  • 财政年份:
    2002
  • 资助金额:
    $ 15.87万
  • 项目类别:

相似海外基金

Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
  • 批准号:
    502556
  • 财政年份:
    2024
  • 资助金额:
    $ 15.87万
  • 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
  • 批准号:
    10659303
  • 财政年份:
    2023
  • 资助金额:
    $ 15.87万
  • 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
  • 批准号:
    10674405
  • 财政年份:
    2023
  • 资助金额:
    $ 15.87万
  • 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
  • 批准号:
    10758772
  • 财政年份:
    2023
  • 资助金额:
    $ 15.87万
  • 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
  • 批准号:
    10676499
  • 财政年份:
    2023
  • 资助金额:
    $ 15.87万
  • 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
  • 批准号:
    2748611
  • 财政年份:
    2022
  • 资助金额:
    $ 15.87万
  • 项目类别:
    Studentship
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
  • 批准号:
    22K05630
  • 财政年份:
    2022
  • 资助金额:
    $ 15.87万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
  • 批准号:
    10532032
  • 财政年份:
    2022
  • 资助金额:
    $ 15.87万
  • 项目类别:
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
  • 批准号:
    10525070
  • 财政年份:
    2022
  • 资助金额:
    $ 15.87万
  • 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
  • 批准号:
    10689017
  • 财政年份:
    2022
  • 资助金额:
    $ 15.87万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了